---
title: Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide
  Maintenance for Mantle Cell Lymphoma
date: '2024-05-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38820500/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240601181226&v=2.18.0.post9+e462414
source: Blood
description: 'While initial therapy of mantle cell lymphoma (MCL) is not standardized,
  bendamustine-rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance
  following induction is often utilized. Thus, the open-label, randomized phase II
  ECOG-ACRIN Cancer Research Group E1411 trial was designed to test two questions:
  1) Does addition of bortezomib to BR induction (BVR) and/or 2) addition of lenalidomide
  to rituximab (LR) maintenance improve progression-free survival (PFS) in patients
  ...'
disable_comments: true
---
While initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine-rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance following induction is often utilized. Thus, the open-label, randomized phase II ECOG-ACRIN Cancer Research Group E1411 trial was designed to test two questions: 1) Does addition of bortezomib to BR induction (BVR) and/or 2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients ...